DCGI approves Phase II/III clinical trail of Covaxin in the age group of 2-18 years

A key step has been taken to make the corona vaccine available to young children as well. The Drug Controller General of India (DCGI) has given permission for clinical trials to find out the effect of Covaxin vaccine, developed by Bharat Biotech, on 2 to 18-year-old.

The decision was taken by the DCGI on the recommendation of a committee of experts to conduct second and third phase testing on people aged 2-18 years. Bharat Biotech will conduct the experiments on 525 volunteers aged between 2-18 year old.

However, DCGI has directed Bharat Biotic to submit the second phase clinical trials safety data and DSMB recommendations to CDSCO before the start of the third phase trials. The experiments will be conducted at various locations across the country, including Delhi and Patna AIIMS. In 28 days period, volunteers will be given two doses to evaluate the results.

Related Articles

- Advertisement -

Latest Articles